BioSpace News Archive

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.

NurExone Biologic Inc.,, a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 102,150 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 58,370 shares of common stock and inducement restricted stock units, covering an aggregate of 43,780 shares of its common stock.

DBV Technologies announced plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value €0.10 per share, from the current ADS Ratio of one ADS to one-half of one ordinary share to a new ADS Ratio of one ADS to one ordinary share.

Ultragenyx Pharmaceutical Inc. reported the grant of 17,180 restricted stock units of the company’s common stock to ten newly hired non-executive officers of the company.

BriaCell Therapeutics Corp. announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common shares of the Company and warrants to purchase up to an aggregate of 2,402,935 common shares of the Company for aggregate gross proceeds of approximately $5.0 million before deducting placement agent fees and other offering expenses.

Medtronic plc, a global leader in healthcare technology, announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field and radiofrequency ablation and high density mapping catheter for the treatment of persistent atrial fibrillation.

Stoke Therapeutics, Inc. announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Achilles Therapeutics plc disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.